Orgenesis and Leidos link up on ranpirnase in COVID-19

22 June 2020

Cell and gene specialist Orgenesis (Nasdaq: ORGS) has entered into a preliminary, non-binding term sheet with Leidos (NYSE: LDOS) to develop and potentially obtain US marketing approval of ranpirnase for the systemic treatment of patients with SARS-CoV-2, the virus that causes COVID-19.

Orgenesis recently acquired the assets of Tamir Biotechnology, including ranpirnase, a broad spectrum anti-viral agent which catalyzes the degradation of RNA, and mediates several essential biological activities, including the regulation of cell proliferation, maturation, differentiation, and cell death.

More than 1,000 patients have been dosed with ranpirnase in previous cancer trials. It has already demonstrated a strong safety and tolerability profile and has also shown preclinical antiviral activity in serious viral diseases, such as cytomegalovirus, influenza, HIV, Ebola, and SARS.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK